Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.